A new test for tuberculosis (TB) could dramatically improve the speed and accuracy of diagnosis for one of the world’s deadliest diseases, enabling health care providers to report results to patients within minutes, according to a study published this week in the journal Angewandte Chemie.
Jeffrey Cirillo, Ph.D., professor at the Texas A&M Health Science Center College of Medicine, in collaboration with GBDbio, a Texas A&M spinoff company, and investigators at Stanford University, have identified a new chemical compound to spot the bacteria that cause TB with a level of sensitivity that currently takes months to produce; and results of the first human clinical trial data are promising. Findings show the test can determine that a patient has tuberculosis with 86 percent sensitivity and 73 percent specificity. Smear microscopy, the most widely used test in the world, has a significantly lower ability to detect TB, ranging between 50 to 60 percent sensitivity.
Although preventable, TB claims three lives every minute, making it the second leading cause of mortality from an infectious disease in the world. Spread through the air when an individual with active TB infection coughs or sneezes, reports show that if left untreated, a person with active TB infects an average of 10 to 15 people each year, leaving a great need for faster, more reliable testing.
Cirillo’s latest breakthrough perfects the technology behind the test. Using a fluorescent substrate, the device targets BlaC – an enzyme produced by the bacteria that cause TB – as an indicator of the bacteria’s presence. Until now, it has not been possible to target a specific TB enzyme for diagnosis.
The Latest on: Tuberculosis
via Google News
The Latest on: Tuberculosis
- The anti-tuberculosis therapeutics market is expected to witness a CAGR of approximately 6.0% over the forecast period, 2019on June 24, 2019 at 2:00 pm
The anti-tuberculosis therapeutics market is expected to witness a CAGR of approximately 6.0% over the forecast period, 2019-2024. Download the full report: https://www.reportbuyer.com/product ... […]
- A roller coaster battle against tuberculosison June 24, 2019 at 1:34 pm
As a tropical country with abundant sunshine, one would think Indonesia would not have any problems with Mycobacterium tuberculosis, the bacteria that causes tuberculosis (TB), as sunshine is supposed ... […]
- Earlier diagnosis and treatment assessment of tuberculosis achieved with pet/cton June 24, 2019 at 1:28 pm
Research presented at the Society of Nuclear Medicine and Molecular Imaging's 2019 Annual Meeting shows that molecular imaging with 18F-FDG positron emission tomography/computed tomography (PET/CT ... […]
- Responsible use of rifampin for the treatment of latent tuberculosis infectionon June 24, 2019 at 2:35 am
A regimen of daily rifampin for 4 months for people with latent tuberculosis infection (LTBI) has recently been shown to have higher treatment completion rates, a more favourable adverse effect ... […]
- What to know about pulmonary tuberculosison June 21, 2019 at 12:29 am
Healthline Media, Inc. would like to process and share personal data (e.g., mobile ad id) and data about your use of our site (e.g., content interests) with our third party partners (see a current ... […]
- Tuberculosis Vaccine Market 2019 | Set Phenomenal Growthon June 20, 2019 at 9:38 am
Jun 20, 2019 (News AIM via COMTEX) -- Increased research and development activities for development of vaccine against TB by companies and intergovernmental organizations is expected to boost growth ... […]
- Spero Therapeutics Announces Collaboration with Bill & Melinda Gates Medical Research Institute to Develop SPR720 for Tuberculosison June 20, 2019 at 5:00 am
CAMBRIDGE, Mass., June 20, 2019 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq:SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and ... […]
- Large-scale chemical–genetics yields new M. tuberculosis inhibitor classeson June 19, 2019 at 10:22 am
New antibiotics are needed to combat rising levels of resistance, with new Mycobacterium tuberculosis (Mtb) drugs having the highest priority. However, conventional whole-cell and biochemical ... […]
- Global Anti-tuberculosis Therapeutics Market Growth, Trends and Forecasts Through 2019-2024 - ResearchAndMarkets.comon June 19, 2019 at 4:59 am
The "Global Anti-tuberculosis Therapeutics Market Growth, Trends and Forecasts Through 2019-2024" report has been added to ResearchAndMarkets.com's offering. The anti-tuberculosis therapeutics market ... […]
- Doctors could use SCORPION venom to fight human infections including tuberculosison June 14, 2019 at 7:10 am
Doctors could use scorpion venom to fight human infections after a study on mice found it can kill bacteria without poisonous effects. The venom contains two chemicals which scientists discovered have ... […]
via Bing News